Solid Biosciences (SLDB) Accounts Payables (2017 - 2026)

Solid Biosciences has reported Accounts Payables for 10 years, with the latest figure at $5.6 million in Q1 2026.

• Quarterly Accounts Payables fell 13.6% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 13.6% YoY) and the FY2025 annual result came in at $3.2 million, down 23.91% from the prior year.
• Accounts Payables rose to $5.6 million in Q1 2026 per SLDB's latest filing, from $3.2 million in the prior quarter.
• Over five years, Accounts Payables peaked at $8.4 million in Q3 2025 and troughed at $1.7 million in Q1 2024.
• A 5-year average of $4.2 million and a median of $4.2 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables slumped 69.08% in 2024, then jumped 272.2% in 2025.
• Over 5 years, Accounts Payables stood at $3.2 million in 2022, then plunged by 37.25% to $2.0 million in 2023, then soared by 108.51% to $4.2 million in 2024, then declined by 23.91% to $3.2 million in 2025, then jumped by 72.55% to $5.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $5.6 million, $3.2 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.